Oncolytic viruses as therapeutic cancer vaccines

David L. Bartlett, Zuqiang Liu, Magesh Sathaiah, Roshni Ravindranathan, Zongbi Guo, Yukai He, Zong S. Guo

Research output: Contribution to journalReview article

143 Citations (Scopus)

Abstract

Oncolytic viruses (OVs) are tumor-selective, multi-mechanistic antitumor agents. They kill infected cancer and associated endothelial cells via direct oncolysis, and uninfected cells via tumor vasculature targeting and bystander effect. Multimodal immunogenic cell death (ICD) together with autophagy often induced by OVs not only presents potent danger signals to dendritic cells but also efficiently cross-present tumor-associated antigens from cancer cells to dendritic cells to T cells to induce adaptive antitumor immunity. With this favorable immune backdrop, genetic engineering of OVs and rational combinations further potentiate OVs as cancer vaccines. OVs armed with GM-CSF (such as T-VEC and Pexa-Vec) or other immunostimulatory genes, induce potent anti-tumor immunity in both animal models and human patients. Combination with other immunotherapy regimens improve overall therapeutic efficacy. Coadministration with a HDAC inhibitor inhibits innate immunity transiently to promote infection and spread of OVs, and significantly enhances anti-tumor immunity and improves the therapeutic index. Local administration or OV mediated-expression of ligands for Toll-like receptors can rescue the function of tumor-infiltrating CD8+ T cells inhibited by the immunosuppressive tumor microenvironment and thus enhances the antitumor effect. Combination with cyclophosphamide further induces ICD, depletes Treg, and thus potentiates antitumor immunity. In summary, OVs properly armed or in rational combinations are potent therapeutic cancer vaccines.

Original languageEnglish (US)
Article number103
JournalMolecular cancer
Volume12
Issue number1
DOIs
StatePublished - Sep 11 2013

Fingerprint

Oncolytic Viruses
Cancer Vaccines
Neoplasms
Immunity
Therapeutics
Dendritic Cells
Cell Death
Bystander Effect
T-Lymphocytes
Histone Deacetylase Inhibitors
Genetic Engineering
Tumor Microenvironment
Toll-Like Receptors
Autophagy
Adaptive Immunity
Neoplasm Antigens
Granulocyte-Macrophage Colony-Stimulating Factor
Immunosuppressive Agents
Innate Immunity
Antineoplastic Agents

Keywords

  • Antigen
  • Antitumor immunity
  • Autophagy
  • Cancer vaccine
  • Cross-presentation
  • Immunogenic cell death
  • Immunotherapy
  • Oncolysis

ASJC Scopus subject areas

  • Molecular Medicine
  • Oncology
  • Cancer Research

Cite this

Bartlett, D. L., Liu, Z., Sathaiah, M., Ravindranathan, R., Guo, Z., He, Y., & Guo, Z. S. (2013). Oncolytic viruses as therapeutic cancer vaccines. Molecular cancer, 12(1), [103]. https://doi.org/10.1186/1476-4598-12-103

Oncolytic viruses as therapeutic cancer vaccines. / Bartlett, David L.; Liu, Zuqiang; Sathaiah, Magesh; Ravindranathan, Roshni; Guo, Zongbi; He, Yukai; Guo, Zong S.

In: Molecular cancer, Vol. 12, No. 1, 103, 11.09.2013.

Research output: Contribution to journalReview article

Bartlett, DL, Liu, Z, Sathaiah, M, Ravindranathan, R, Guo, Z, He, Y & Guo, ZS 2013, 'Oncolytic viruses as therapeutic cancer vaccines', Molecular cancer, vol. 12, no. 1, 103. https://doi.org/10.1186/1476-4598-12-103
Bartlett DL, Liu Z, Sathaiah M, Ravindranathan R, Guo Z, He Y et al. Oncolytic viruses as therapeutic cancer vaccines. Molecular cancer. 2013 Sep 11;12(1). 103. https://doi.org/10.1186/1476-4598-12-103
Bartlett, David L. ; Liu, Zuqiang ; Sathaiah, Magesh ; Ravindranathan, Roshni ; Guo, Zongbi ; He, Yukai ; Guo, Zong S. / Oncolytic viruses as therapeutic cancer vaccines. In: Molecular cancer. 2013 ; Vol. 12, No. 1.
@article{29b118b59e0c4b89af52d76f286e3e26,
title = "Oncolytic viruses as therapeutic cancer vaccines",
abstract = "Oncolytic viruses (OVs) are tumor-selective, multi-mechanistic antitumor agents. They kill infected cancer and associated endothelial cells via direct oncolysis, and uninfected cells via tumor vasculature targeting and bystander effect. Multimodal immunogenic cell death (ICD) together with autophagy often induced by OVs not only presents potent danger signals to dendritic cells but also efficiently cross-present tumor-associated antigens from cancer cells to dendritic cells to T cells to induce adaptive antitumor immunity. With this favorable immune backdrop, genetic engineering of OVs and rational combinations further potentiate OVs as cancer vaccines. OVs armed with GM-CSF (such as T-VEC and Pexa-Vec) or other immunostimulatory genes, induce potent anti-tumor immunity in both animal models and human patients. Combination with other immunotherapy regimens improve overall therapeutic efficacy. Coadministration with a HDAC inhibitor inhibits innate immunity transiently to promote infection and spread of OVs, and significantly enhances anti-tumor immunity and improves the therapeutic index. Local administration or OV mediated-expression of ligands for Toll-like receptors can rescue the function of tumor-infiltrating CD8+ T cells inhibited by the immunosuppressive tumor microenvironment and thus enhances the antitumor effect. Combination with cyclophosphamide further induces ICD, depletes Treg, and thus potentiates antitumor immunity. In summary, OVs properly armed or in rational combinations are potent therapeutic cancer vaccines.",
keywords = "Antigen, Antitumor immunity, Autophagy, Cancer vaccine, Cross-presentation, Immunogenic cell death, Immunotherapy, Oncolysis",
author = "Bartlett, {David L.} and Zuqiang Liu and Magesh Sathaiah and Roshni Ravindranathan and Zongbi Guo and Yukai He and Guo, {Zong S.}",
year = "2013",
month = "9",
day = "11",
doi = "10.1186/1476-4598-12-103",
language = "English (US)",
volume = "12",
journal = "Molecular Cancer",
issn = "1476-4598",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Oncolytic viruses as therapeutic cancer vaccines

AU - Bartlett, David L.

AU - Liu, Zuqiang

AU - Sathaiah, Magesh

AU - Ravindranathan, Roshni

AU - Guo, Zongbi

AU - He, Yukai

AU - Guo, Zong S.

PY - 2013/9/11

Y1 - 2013/9/11

N2 - Oncolytic viruses (OVs) are tumor-selective, multi-mechanistic antitumor agents. They kill infected cancer and associated endothelial cells via direct oncolysis, and uninfected cells via tumor vasculature targeting and bystander effect. Multimodal immunogenic cell death (ICD) together with autophagy often induced by OVs not only presents potent danger signals to dendritic cells but also efficiently cross-present tumor-associated antigens from cancer cells to dendritic cells to T cells to induce adaptive antitumor immunity. With this favorable immune backdrop, genetic engineering of OVs and rational combinations further potentiate OVs as cancer vaccines. OVs armed with GM-CSF (such as T-VEC and Pexa-Vec) or other immunostimulatory genes, induce potent anti-tumor immunity in both animal models and human patients. Combination with other immunotherapy regimens improve overall therapeutic efficacy. Coadministration with a HDAC inhibitor inhibits innate immunity transiently to promote infection and spread of OVs, and significantly enhances anti-tumor immunity and improves the therapeutic index. Local administration or OV mediated-expression of ligands for Toll-like receptors can rescue the function of tumor-infiltrating CD8+ T cells inhibited by the immunosuppressive tumor microenvironment and thus enhances the antitumor effect. Combination with cyclophosphamide further induces ICD, depletes Treg, and thus potentiates antitumor immunity. In summary, OVs properly armed or in rational combinations are potent therapeutic cancer vaccines.

AB - Oncolytic viruses (OVs) are tumor-selective, multi-mechanistic antitumor agents. They kill infected cancer and associated endothelial cells via direct oncolysis, and uninfected cells via tumor vasculature targeting and bystander effect. Multimodal immunogenic cell death (ICD) together with autophagy often induced by OVs not only presents potent danger signals to dendritic cells but also efficiently cross-present tumor-associated antigens from cancer cells to dendritic cells to T cells to induce adaptive antitumor immunity. With this favorable immune backdrop, genetic engineering of OVs and rational combinations further potentiate OVs as cancer vaccines. OVs armed with GM-CSF (such as T-VEC and Pexa-Vec) or other immunostimulatory genes, induce potent anti-tumor immunity in both animal models and human patients. Combination with other immunotherapy regimens improve overall therapeutic efficacy. Coadministration with a HDAC inhibitor inhibits innate immunity transiently to promote infection and spread of OVs, and significantly enhances anti-tumor immunity and improves the therapeutic index. Local administration or OV mediated-expression of ligands for Toll-like receptors can rescue the function of tumor-infiltrating CD8+ T cells inhibited by the immunosuppressive tumor microenvironment and thus enhances the antitumor effect. Combination with cyclophosphamide further induces ICD, depletes Treg, and thus potentiates antitumor immunity. In summary, OVs properly armed or in rational combinations are potent therapeutic cancer vaccines.

KW - Antigen

KW - Antitumor immunity

KW - Autophagy

KW - Cancer vaccine

KW - Cross-presentation

KW - Immunogenic cell death

KW - Immunotherapy

KW - Oncolysis

UR - http://www.scopus.com/inward/record.url?scp=84883642231&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883642231&partnerID=8YFLogxK

U2 - 10.1186/1476-4598-12-103

DO - 10.1186/1476-4598-12-103

M3 - Review article

VL - 12

JO - Molecular Cancer

JF - Molecular Cancer

SN - 1476-4598

IS - 1

M1 - 103

ER -